Assorted news from last week: Adding a novel anti-GD2 antibody (hu14.18K322A) to induction chemotherapy for children with newly diagnosed high-risk neuroblastoma yielded impressive survival outcomes
Assorted news from last week: According to Jim Morris, investigative reporter for Public Health Watch, “for the foreseeable future, thousands of children will continue to
Assorted news from last week: A primer on where the Centers for Medicare and Medicaid Services see Medicaid and the Children’s Health Insurance Program (CHIP)
Assorted news from last week: Provocative article written by pediatric cancer advocates, including several CAC2 members — innovation can be crippled by commercialization — meaning
Assorted news from last week: Save the Date: CureFest 2022 will be held Sep. 24 and 25 in Washington, DC. Second Paediatric Strategy Forum for
Assorted news from last week: Save the Date: CureFest 2022 will be held Sep. 24 and 25 in Washington, DC. The Children’s Brain Tumor Network
Assorted news from last week: Save the Date: CureFest 2022 will be held Sep. 24 and 25 in Washington, DC. The World Health Organization (WHO)
Assorted news from last week: CAC2 Ethics Think Tank will present a paper entitled Cultivating Ethically Sustainable Relationships with Stakeholders When Non-Profits Fund Pediatric Cancer
Assorted news from last week: The FDA has granted a rare pediatric disease designation (RPDD) to lutetium-177(177Lu)-omburtamab-DTPA for use as a potential therapeutic option in
Assorted news from last week: CAC2 Member Mary Beth Collins, highlights the importance of Childhood Cancer License Plates, how they amplify awareness efforts, the advocacy
